Primary screening approach for anti-inflammatory agents utilizing an in vivo and a new in vitro method.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001337:Autonomic Agents / Q000494:pharmacology; D001391:Azo Compounds; D002351:Carrageenan / Q000494:pharmacology; D002474:Cell-Free System; D002746:Chlorpromazine / Q000494:pharmacology; D004487:Edema / Q000139:chemically induced; D005189:False Positive Reactions; D005559:Formamides; D005966:Glucuronidase; D007099:Imipramine / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008099:Liver / Q000166:cytology / Q000187:drug effects; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008930:Mitochondria, Liver / Q000187:drug effects; D010634:Phenobarbital / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases; D051381:Rats; D013429:Sulfatases; D014291:Trimeprazine / Q000494:pharmacology
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D001337:Autonomic Agents; D001391:Azo Compounds; D005559:Formamides; D007166:Immunosuppressive Agents; D014291:Trimeprazine; D002351:Carrageenan; D010744:Phosphoric Monoester Hydrolases; D013429:Sulfatases; D005966:Glucuronidase; D007099:Imipramine; D002746:Chlorpromazine; D010634:Phenobarbital